Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer (EnergiePancrea)

Center Eugene Marquis

Status: Terminated

Conditions: Metastatic Pancreatic Cancer

Treatments: Other: Measure of resting energetic expenditure

Study type: Interventional

Funder types: Other

Identifiers

NCT02921646

2015-4-32-004

Details and patient eligibility

About

The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pancreatic metastatic cancer
• Patient older than 18 years
• Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.
• At least one measurable target lesion
• Patient signed consent for Energie-Pancreas study participation

Exclusion criteria

• Other concomitant cancer
• Major general status alteration ( Performance status = 3 or 4 at inclusion)
• Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (< 1 month), ongoing Healing, hyperthyroidism.
• Smoker
• Patient deprived of his liberty, under guardianship, curator.
• Pregnant patient or breastfeeding
• Claustrophobic patient

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

energetic expenditure measure

Other group

Description:

To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.

Treatment:

Other: Measure of resting energetic expenditure